

PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links With Immunizations

Eric Fombonne, Rita Zakarian, Andrew Bennett, Linyan Meng and Diane McLean-Heywood

Pediatrics 2006;118:139-150

DOI: 10.1542/peds.2005-2993

This information is current as of August 1, 2006

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://www.pediatrics.org/cgi/content/full/118/1/e139>

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2006 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links With Immunizations

Eric Fombonne, MD^a, Rita Zakarian, MEd^a, Andrew Bennett, PhD, CPsych^b, Linyan Meng, MSc^a, Diane McLean-Heywood, MA^b

^aDepartment of Psychiatry, McGill University, Montreal Children's Hospital, Montreal, Quebec, Canada; ^bLester B. Pearson School Board, Montreal, Quebec, Canada

In the United Kingdom, Dr Fombonne has provided advice on the epidemiology and clinical aspects of autism to scientists advising parents, to vaccine manufacturers, and to several government committees between 1998 and 2001. Since June 2004, Dr Fombonne has been an expert witness for vaccine manufacturers in US thimerosal litigation. None of his research has ever been funded by the industry.

ABSTRACT

BACKGROUND. The prevalence of pervasive developmental disorders has increased in recent years. Links with the measles component of the measles-mumps-rubella vaccine and the cumulative exposure to thimerosal through other vaccines have been postulated.

OBJECTIVES. The purpose of this work was to estimate the pervasive developmental disorder prevalence in Montreal, Canada, in cohorts born from 1987 to 1998 and evaluate the relationship of trends in pervasive developmental disorder rates with: (1) changes in cumulative exposure to ethylmercury (thimerosal) occurring through modifications in the immunization schedule of young children and (2) trends in measles-mumps-rubella vaccination use rates and the introduction of a 2-measles-mumps-rubella dosing schedule during the study period.

METHODS. We surveyed 27 749 children born from 1987 to 1998 attending 55 schools from the largest Anglophone school board. Children with pervasive developmental disorders were identified by a special needs team. The cumulative exposure by age 2 years to thimerosal was calculated for 1987–1998 birth cohorts. Ethylmercury exposure ranged from medium (100–125 μg) from 1987 to 1991 to high (200–225 μg) from 1992 to 1995 to nil from 1996 onwards when thimerosal was entirely discontinued. Measles-mumps-rubella coverage for each birth cohort was estimated through surveys of vaccination rates. The immunization schedule included a measles-mumps-rubella single dose at 12 months of age up to 1995, and a second measles-mumps-rubella dose at 18 months of age was added on after 1996.

RESULTS. We found 180 children (82.8% males) with a pervasive developmental disorder diagnosis who attended the surveyed schools, yielding a prevalence for pervasive developmental disorder of 64.9 per 10 000. The prevalence for specific pervasive developmental disorder subtypes were, for autistic disorder: 21.6 of 10 000; for pervasive developmental disorder not otherwise specified: 32.8 of 10 000; and for Asperger syndrome: 10.1 of 10 000. A statistically significant linear increase in pervasive developmental disorder prevalence was noted during the study period. The prevalence of pervasive developmental disorder in thimerosal-free birth cohorts was significantly higher than that in thimerosal-exposed cohorts (82.7 of 10 000 vs 59.5 of 10 000). Using logistic regression models of the preva-

www.pediatrics.org/cgi/doi/10.1542/peds.2005-2993

doi:10.1542/peds.2005-2993

Key Words

school-aged child, autism, Asperger syndrome, childhood disintegrative disorder, pervasive developmental disorder, prevalence, epidemiology, immunization, thimerosal, ethylmercury, measles vaccine, MMR

Abbreviations

PDD—pervasive developmental disorder
 PDDNOS—pervasive developmental disorder not otherwise specified
 CDD—childhood disintegrative disorder
 MMR—measles-mumps-rubella
 LBPSB—Lester B. Pearson School Board
 MEQ—Ministry of Education of Quebec
 DSM-IV—Diagnostic and Statistical Manual of Mental Disorders—Fourth Edition
 Hib—*Haemophilus influenzae* type b
 CI—confidence interval
 OR—odds ratio
df—degrees of freedom

Accepted for publication Feb 15, 2006

Address correspondence to Eric Fombonne, MD, Montréal Children's Hospital, 4018 Ste-Catherine West, Montreal, Quebec, Canada H3Z 1P2. E-mail: eric.fombonne@mcgill.ca

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275). Copyright © 2006 by the American Academy of Pediatrics

lence data, we found no significant effect of thimerosal exposure used either as a continuous or a categorical variable. Thus, thimerosal exposure was unrelated to the increasing trend in pervasive developmental disorder prevalence. These results were robust when additional analyses were performed to address possible limitations because of the ecological nature of the data and to evaluate potential effects of misclassification on exposure or diagnosis. Measles-mumps-rubella vaccination coverage averaged 93% during the study interval with a statistically significant decreasing trend from 96.1% in the older birth cohorts (1988–89) to ~92.4% in younger birth cohorts (1996–1998). Thus, pervasive developmental disorder rates significantly increased when measles-mumps-rubella vaccination uptake rates significantly decreased. In addition, pervasive developmental disorder prevalence increased at the same rate before and after the introduction in 1996 of the second measles-mumps-rubella dose, suggesting no increased risk of pervasive developmental disorder associated with a 2-measles-mumps-rubella dosing schedule before age 2 years. Results held true when additional analyses were performed to test for the potential effects of misclassification on exposure or diagnostic status. Thus, no relationship was found between pervasive developmental disorder rates and 1- or 2-dose measles-mumps-rubella immunization schedule.

CONCLUSIONS. The prevalence of pervasive developmental disorder in Montreal was high, increasing in recent birth cohorts as found in most countries. Factors accounting for the increase include a broadening of diagnostic concepts and criteria, increased awareness and, therefore, better identification of children with pervasive developmental disorders in communities and epidemiologic surveys, and improved access to services. The findings ruled out an association between pervasive developmental disorder and either high levels of ethylmercury exposure comparable with those experienced in the United States in the 1990s or 1- or 2-dose measles-mumps-rubella vaccinations.

PERVASIVE DEVELOPMENTAL DISORDERS (PDDs) are characterized by marked impairments in reciprocal social interaction, language, and communication and by the presence of repetitive/stereotypic patterns of behavior and interests.¹ PDDs refer to a class of disorders that is composed of several diagnoses, including autistic disorder, PDD not otherwise specified (PDDNOS), Asperger syndrome, and childhood disintegrative disorder (CDD). Rett disorder has been historically listed in the PDDs to enhance differential diagnosis, but it is usually not included in studies of children with PDD. Investigations of the causes of PDDs are progressing, especially with respect to molecular genetic studies.² Early intensive be-

havioral interventions can significantly alter developmental trajectories of preschoolers and may lead to substantial cognitive and language gains in some children.^{3,4} Yet, some children make little gains,⁴ and the long-term outcome of PDDs, and particularly that of autistic disorder, is still guarded.⁵ Services for children with PDDs are in great need of development in many countries, including Canada.

Epidemiologic surveys of PDDs have multiplied in recent years. Reviews^{6,7} and surveys^{8,9} conducted in the last 5 years have consistently reported prevalence rates of ~0.6% for the whole PDD spectrum. This roughly threefold increase in PDD prevalence over time¹⁰ has generated concerns about a possible epidemic, although a true secular increase in the incidence of the disorder has not yet been demonstrated.^{7,11,12} Rather, factors such as broadening of the diagnostic concepts, increased awareness of the disorder, and improved detection in surveys likely account for a substantial part of the increased prevalence.^{7,12–15} If changes in the incidence of PDDs were demonstrated, they might point toward environmental risk factors contributing to the etiology of the disorder, with or without gene interactions. Few environmental exposures that occur during the prenatal period have been related to increased risk of PDDs, and such factors account for only a tiny fraction of the population risk.¹⁶ However, hypotheses linking vaccinations to autism have been raised since 1998. The first hypothesis implicated the measles component of the measles-mumps-rubella (MMR) vaccine that is usually given to children between 12 and 15 months of age in most countries.¹⁷ Subsequent epidemiologic investigations of this hypothesis have consistently failed to establish an association between MMR and autism in cohort,¹⁸ case-control,^{19,20} and ecological studies.^{21–23} Furthermore, clinical studies have also failed to identify a clinical phenotype characterizing a smaller group of autistic children presumably at risk of MMR-induced autism.²⁴ Recent reviews of the MMR hypothesis by an ad hoc committee of the Institute of Medicine and the Cochrane collaboration concluded that the evidence favored the rejection of this hypothesis.^{25,26} Yet, concerns about MMR safety have persisted among parents of autistic children and the lay public, leading to decreased uptake of the vaccine and subsequent measles epidemic outbreaks.²⁷ In addition, no study has ever tested the effects of a 2-MMR dosing schedule in toddlers.

A second hypothesis implicated the cumulative exposure of young children until age 2 years to thimerosal, a vaccine stabilizer that contains ~50% ethylmercury. This hypothesis is entirely distinct from the previous one, because MMR vaccines never contained any thimerosal because it would inactivate a live vaccine. A review of the US immunization schedule concluded that the cumulative exposure of children at age 2 years exceeded US Food and Drug Administration and US Envi-

ronmental Protection Agency recommended safety limits and led to the suggestion in the United States to remove thimerosal from vaccine preparations altogether.^{28,29} Subsequent epidemiological research on the thimerosal-autism presumed association has been consistently negative, with cohort³⁰⁻³³ and ecological^{34,35} studies failing to show any association. The only published "positive" studies have all been performed by 1 author^{36,37} and have been considered to be noncontributing because of their poor methodology.^{25,38} By and large, biological studies of ethylmercury exposure have also failed to support the thimerosal hypothesis.^{25,39,40} Despite the accumulation of negative studies, concerns from the public have not been entirely alleviated, and fears continue to be fueled by well-publicized media accounts of a spectacular nature.^{41,42} Unfortunately, these unsubstantiated claims have led to the uncontrolled development of chelation therapies of autistic children in North America. These therapies are not only of unproven efficacy, but they also can be dangerous, as unfortunately shown in the recent death of a 5-year-old boy with autism.⁴³

Only 1 survey of autism spectrum disorders has thus far been performed in Canada.⁴⁴ The authors screened 20 800 children aged 4 to 6 years residing in a specific region of Nova Scotia in 1985 and, using new research diagnostic criteria, obtained a prevalence of 10.1 per 10 000 children for autism. This survey did not generate a figure for the whole PDD spectrum, and dates back ~20 years. No epidemiological survey has ever been conducted in Quebec or in other parts of Canada. As other provinces in Canada, Quebec has a universal health insurance system that ensures free access to medical care. As a result, immunization policies are effectively implemented at the population level. In the last 20 years, several changes in the official immunization schedule occurred that provided an opportunity to assess the effects, if any, of both variations in thimerosal exposure and MMR vaccine coverage on PDD rates in successive birth cohorts.

We report here on a prevalence survey of PDDs that we conducted in 2003–2004 in a Montreal school board. The goals of this survey were to (1) generate an estimate of the prevalence of the whole PDD spectrum that could be applied to the province of Quebec for purposes of service planning, (2) estimate the prevalence of specific diagnostic subtypes within the PDD spectrum, (3) evaluate trends in prevalence rates in successive birth cohorts, (4) examine the relationship, if any, between trends in autism rates and exposure to varying levels of thimerosal during the study period, and (5) examine the relationship, if any, between trends in autism rates and MMR vaccination uptake. Compared with previous research on immunization and autism, this study uniquely examines exposure to high levels of thimerosal and also

tests for the effects of a 2-dose MMR schedule before age 2 years.

METHODS

Subjects

In the province of Quebec, children are educated either in English or French schools. Schools belong to school boards that are also organized according to language. The largest school board for Anglophone children in Quebec is the Lester B. Pearson School Board (LBPSB), which provides education to individuals in the south and western parts of the greater Montreal area. The LBPSB has 55 schools (45 elementary and 10 secondary) and provides education from kindergarten through grade 11. October 1, 2003, was chosen as the survey date. As of October 1, 2003, a total of 27 749 children were registered within the LBPSB.

Case Identification

In Quebec, children with special education needs are either integrated, segregated within a regular school, or placed within a special school. Funding, in addition to the base grant received for all students, is provided to school boards when the special needs of a student are classifiable according to criteria established by the Ministry of Education of Quebec (MEQ). Of the 10 medical or psychiatric categories allowing the school to receive extra funding from the MEQ, PDD is one of the conditions that lead to the highest incremental funding. Each year, a list of children with identified PDDs attending any one of the schools within each of the province school boards is sent to the MEQ by September 30. Using this list, the MEQ determines the amount of extra funding each school board receives to meet the needs of children with PDDs. Until 2000, children with PDDs were administratively identified only if their diagnosis was specifically stated as autism (code 51). In 2000, the category was broadened to autism spectrum disorder (code 50). In addition, the LBPSB has a special support team to monitor the progress of children with PDD in its schools. This team keeps a list of children with a PDD diagnosis, which is updated on a weekly basis. The children with PDD who are the focus of this study were identified via this list. In grade 11, several subjects ($N = 10$) with a PDD diagnosis were aged 17 to 21 years, as by provincial law students with special needs can extend their secondary education up to age 21. Because the count of these older subjects could not be related to a meaningful denominator, they were excluded from the survey.

Data

Children with a diagnosis of PDD were identified by school personnel and given a study code to preserve the anonymity of the data. Children's diagnoses were not

verified by direct assessments, but it is worth noting that a majority of these children ($N = 155$; 86.1%) have been diagnosed at the Montreal Children's Hospital. School personnel further identified the diagnostic subtype using *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition* (DSM-IV) diagnostic criteria, age, grade, and school the child was attending. When available, place of birth was recorded as well. Individual immunization data were not available for study subjects. Denominators used for further prevalence calculations were obtained through the LBPSB and included the total number of children (male/female) in each grade registered in any of the schools at the LBPSB. Thus, prevalence rates could be computed for each grade by dividing the number of children with a PDD diagnosis in a given grade by the corresponding denominator. Age-specific prevalence rates could not be precisely derived, because the dates of birth were only available for the PDD children but not for the whole school population. However, we estimated the birth year of the entire school population based on their grade attendance. Thus, children in kindergarten were assumed to all be born in 1998, children in grade 1 in 1997, and so forth. We performed a check that this imputation method was correct by examining the correspondence between grade and year of birth using dates of birth from the PDD sample. In 9 of 11 comparisons, the mode of year of birth of the sample coincided with the estimated year of birth, providing confidence in our method. Although this method is not entirely accurate, the trend analysis was not influenced by potential birth cohort misclassification, as shown below.

Immunization Exposure Data

In Quebec, the schedule of immunization is defined by the Ministry of Health and Social Services.⁴⁵⁻⁴⁹ Immunizations are administered by general practitioners, family doctors, and pediatricians in both community clinics and private offices and at no cost for the family.

Vaccine Coverage

Vaccine coverage has traditionally been very good in Quebec.⁵⁰ Several surveys have been performed in Quebec to evaluate the extent of adequate vaccine coverage among young children in Quebec. The definition of adequate vaccine coverage has varied between surveys, reflecting changes over time in the immunization schedule. Adequate vaccination was usually defined as the appropriate number of diphtheria-tetanus toxoids-pertussis, polio, *Haemophilus influenzae* type b (Hib), and MMR vaccine doses received by 24 to 30 months of age. Rates of adequate vaccine coverage have typically varied between 85% and 90% as illustrated by adequate coverage of 85.2% in 520 children aged 24 to 30 months,⁵¹ of 87.7% among children aged 24 to 30 months born in 1989 and 1990,⁵² and of 89.8% in 1270 children aged 24 months.⁵³ Thus, the vast majority of children born in

Quebec are adherent to the official immunization schedule.⁵⁴

Thimerosal/Ethylmercury Exposure

The schedule of immunization in Quebec and its changes over time can be consulted from public health official documentation.⁴⁵⁻⁴⁹ From 1985 to 1987, a combined diphtheria, pertussis (cellular), tetanus vaccine was recommended at ages 2, 4, 6, and 18 months and 4 to 6 years. Each dose contained 50 μg of thimerosal (ie, 25 μg of ethylmercury), leading to a cumulative exposure of 100 μg of ethylmercury by age 2. In 1988, a Hib vaccine was added to the schedule at 18 months of age. Because each dose contained 50 μg of thimerosal, the cumulative exposure to ethylmercury from 1988 went up to 125 μg by age 2 years. In 1992, the immunization schedule recommended that the Hib be administered at 2, 4, 6, and 18 months, with each dose containing 50 μg of thimerosal. Thus, from 1992, the cumulative exposure to ethylmercury by age 2 years reached 200 μg .

From 1987 to 1995, the polio vaccine was administered separately at 2, 4, and 18 months and 4 to 6 years. The polio vaccine did not contain any thimerosal. In 1996, the polio vaccine and the Hib vaccine were combined with diphtheria, pertussis (cellular), tetanus vaccine in a thimerosal-free pentavaccine administered at 2, 4, 6 and 18 months of age, with a polio, pertussis (cellular), tetanus booster (thimerosal-free) at 4 to 6 years. From 1998 onward, the acellular pertussis vaccine replaced the cellular vaccine in the combined vaccine. Thus, from 1996 onward, all immunizations were thimerosal-free, leading to a nil cumulative ethylmercury exposure through vaccinations by age 2 years.

In addition, from January to March 1993, a mass immunization campaign against meningococcal disease was performed among subjects aged 6 months to 20 years.⁵⁵ In $\sim 10\%$ of the cases, the vaccine used contained 50 μg of thimerosal. Therefore, in a small proportion of children, the cumulative exposure to ethylmercury by age 3 may have reached 150 (instead of 125) μg of ethylmercury in children born from March 1990 to December 1991 and 225 μg of ethylmercury in children born from January 1992 to September 1992.

MMR Immunization

MMR was incorporated in the official schedule of immunizations of Quebec in 1976. The recommended age for administration of MMR was 1 year of age up to 1996. Since 1996, the recommendation was to administer 2 MMR doses, at 12 and 18 months of age. Data on MMR uptake for the study period were available through the Direction de Santé Publique de la Capitale Nationale (N. Boulianne, BN, MSc, written communication, 2005). These data were routinely collected in the region of Quebec among 5-year-old children attending kindergarten during the years 1993-2004 (ie, for birth cohorts

from 1988–1998). Vaccination records from children were used as the main source of information to document MMR vaccination and its date. When this information was not available, vaccination status of the children was obtained through consultation of the regional vaccination registry or else through direct contact with doctor's practices, both from community clinics or private offices. Data were unavailable for 2 birth cohorts (1987 and 1997) during the study interval. Surveys were performed annually on a total population of 35 643 children, with each annual sample fluctuating in size between 2234 in 1990 to 5914 in 1993. For the 10 birth cohorts with available data, the average MMR uptake in Quebec was 93.2% during the whole period, ranging from 91.3% in the 1992 birth cohort to 96.4% in the 1989 birth cohort.

Statistical Analysis

Data were analyzed by using SAS 8.2 (SAS Institute, Cary, NC) statistical software.⁵⁶ A conventional *P* value of .05 was chosen as a criterion for statistical significance. Conventional statistical tests were used for categorical variables. 95% confidence intervals (CIs) for prevalence estimates were calculated using the hypergeometric distribution (Fisher's exact interval). To assess the relationship between prevalence estimates and thimerosal exposure data, prevalence estimates for each successive birth cohort were modeled by using the SAS Logistic procedure and the events/trials syntax.⁵⁷ Birth cohort and level of ethylmercury exposure for each birth cohort were used as predictor variables in modeling the data. Birth cohort was treated as a continuous predictor. Level of ethylmercury exposure was used either as a continuous or a categorical predictor. When used continuously, the ethylmercury level for each birth cohort was that obtained from the official immunization schedule (range: 0–225 µg). A categorical ethylmercury exposure variable was created with 3 levels (0 = zero exposure; 1 = medium exposure [ie, between 100 and 150 µg ethylmercury]; and 2 = high exposure [≥200 µg ethylmercury]).

RESULTS

Prevalence

Of 27 749 children enrolled in the LBPSB, a total of 180 children were identified with a PDD diagnosis. This

translates into a prevalence of all PDD combined of 64.9 per 10 000 children (95% CI: 55.8–75.0). Half of the children with PDD (*N* = 91; 50.6%) had a diagnosis of PDDNOS. Of the remaining 89 children (49.4%), 60 children (33.3%) had a diagnosis of autistic disorder, 28 children (15.6%) had a diagnosis of Asperger syndrome, and 1 child (0.6%) had CDD. The corresponding prevalence figures are: for autistic disorder: 21.6 of 10 000 (95% CI: 16.5–27.8 of 10 000); for PDDNOS: 32.8 of 10 000 (95% CI: 26.4–40.2 of 10 000); for Asperger syndrome: 10.1 of 10 000 (95% CI: 6.7–14.6 of 10 000); and for CDD: 0.4 of 10 000 (95% CI: 0.0–2.0 of 10 000). Table 1 illustrates the gender and age distribution by PDD diagnostic subtypes. Consistent with other studies, the data show a preponderance of males in the PDD sample (82.8%), translating into a 4.8:1 male/female ratio. Surprisingly, the male/female ratio was lower in the Asperger group than in the other 2 groups. The statistically significant age effect reflects the marked change in PDD prevalence and distribution of PDD subtypes over time (1987–1998).

Figure 1 provides prevalence estimates calculated separately for each grade that are used here as a proxy indicator for birth cohort. There was an important variability in prevalence estimates by grade, with the highest prevalence of 107.6 per 10 000 being observed in kindergarten (eg, youngest children born in 1998), and the lowest prevalence being of 27.5 per 10 000 for grade 10, among children roughly aged 16 years. Prevalence was relatively steady for grades 8 through 11. Using logistic regression, a statistically significant effect on prevalence was found for birth cohort (odds ratio [OR]: 1.10; 95% CI: 1.05–1.15), suggesting an average annual increase of 10% in prevalence rate. Inclusion of quadratic terms for birth cohort did not improve the fit of the model, suggesting that the increase of prevalence was linear during the study period.

Autism and Thimerosal

Figure 2 charts prevalence estimates and thimerosal exposure levels for each birth cohort from 1987 through 1998. A visual inspection of the data indicates that PDD rates started to increase before the change from medium (1987–1991) to high (1992–1995) exposure levels, and, even more convincingly, it shows that rates continued to

TABLE 1 Gender and Age Distribution by PDD Diagnostic Subtypes

Variable	Autism (<i>N</i> = 61), <i>n</i> (%) ^a	PDDNOS (<i>N</i> = 91), <i>n</i> (%)	Asperger (<i>N</i> = 28), <i>n</i> (%)	All PDD (<i>N</i> = 180), <i>n</i> (%)	<i>P</i>
Male	51 (83.6)	79 (86.8)	19 (67.9)	149 (82.8)	.066
Age, y					
5–7	30 (49.2)	17 (18.7)	2 (7.1)	49 (27.2)	
8–10	13 (21.3)	44 (48.4)	10 (35.7)	67 (37.2)	<.001
11–13	10 (16.4)	21 (23.1)	7 (25.0)	38 (21.1)	
≥14	8 (13.1)	9 (9.9)	9 (32.1)	26 (14.4)	

^a The subject with CDD has been included in the autism group.

FIGURE 1
MMR vaccine coverage and PDD rates over time.





FIGURE 2
Birth cohort prevalence rates and ethylmercury exposure. Dotted lines take into account the additional ethylmercury exposure because of a mass vaccination campaign against meningitis (see text).

rise after total discontinuation of thimerosal (1996–1998). The highest prevalence rate was found in the 1998 thimerosal-free birth cohort. To assess this trend statistically, we first compared the average prevalence in thimerosal-free birth cohorts (1996–1998) to that of previous thimerosal-exposed birth cohorts (1987–1995). The results indicate a significantly (OR: 1.39; 95% CI: 1.01–1.92; $P < .05$) higher prevalence of PDD in thimerosal-free cohorts (82.7 of 10 000; 95% CI: 62.0–108.0 of 10 000) compared with thimerosal-exposed cohorts (59.5 of 10 000; 95% CI: 49.6–70.8 of 10 000).

Logistic regression modeling of the data was then performed. Because birth cohort was associated with both level of thimerosal exposure and prevalence of PDD, birth cohort was entered in the model to adjust for its confounding effect. We then added in thimerosal exposure to the model to evaluate its specific contribu-

tion to the trend in prevalence. When thimerosal exposure was used as a continuous variable, no significant effect was found ($\chi^2 = 2.54$; degrees of freedom [df] = 1; $P = .11$). Similarly, when thimerosal exposure was entered as a categorical variable, no effect of thimerosal exposure on rates of PDD could be found ($\chi^2 = 3.24$; $df = 2$; $P = .20$). In both models, birth cohort exerted a significant effect on prevalence rates (OR: 1.10; 95% CI: 1.05–1.15), and adequate fit was obtained (Hosmer Lemeshow $\chi^2 = 7.90$; $df = 10$; $P > .50$). Thus, thimerosal exposure was unrelated to the increasing trend in PDD prevalence.

We took several additional steps to assess the robustness of these results. First, to account for the slight increase of levels of thimerosal exposure for children included in the mass immunization campaign against meningococcal disease, we allocated new values of thimerosal exposure measured continuously for the

1990 and 1991 birth cohorts (150 μg instead of 125 μg) and for the 1992 birth cohort (225 μg instead of 200 μg ; see Fig 2). Because this did not affect our exposure categories, only analyses with the continuous thimerosal variable were repeated. The results remained unchanged with no statistically significant effect of thimerosal on prevalence rates of PDDs (data not shown).

Second, because of the ecological nature of the data set, individual thimerosal exposure data were not known. However, places of birth were available on all 180 of the PDD subjects. Of the 180 subjects, 158 (87.8%) were born in Quebec and were, therefore, extremely likely to have followed the immunization schedule. The proportion of children born in Quebec did not vary across the 3 thimerosal exposure periods ($\chi^2 = 0.60$; $df = 2$; $P > .50$). Analyses were repeated on the subsample of Quebec-born subjects. Prevalence rate of PDDs increased from 40.6 of 10 000 in 1987 to 102.5 of 10 000 in 1998, the linear increase being statistically significant (OR: 1.10; 95% CI: 1.05–1.16; $P < .0001$). The PDD prevalence in thimerosal-free 1996–1998 birth cohorts (74.9 of 10 000; 95% CI: 55.3–99.1 of 10 000) was significantly higher (OR: 1.46; 95% CI: 1.04–2.05; $P = .031$) than that in thimerosal-exposed 1987–1995 birth cohorts (51.6 of 10 000; 95% CI: 42.4–62.1 of 10 000). Logistic regression models to test for the effects of thimerosal among Quebec-born subjects led to negative results similar to what was obtained in the whole sample. More specifically, when the effects of birth cohort were already accounted for, the effect of thimerosal was nonsignificant when treated either as a continuous exposure ($\chi^2 = 1.60$; $df = 1$; $P = .21$) or as a categorical exposure variable ($\chi^2 = 2.21$; $df = 2$; $P = .33$). In both analyses, birth cohort effects were significant (OR: 1.10; 95% CI: 1.05–1.16; $P < .0001$), and goodness-of-fit statistics were not significant, indicative of a good model fit.

Third, whereas exposure data were precisely calculated for each birth cohort, our method of estimation of birth cohort was indirect, raising the possibility of some misclassification on exposure. To address this problem, we rescored the year of birth by either subtracting or adding 1. This created 2 new data sets (1986–1997 and 1988–1999) with which all of the above analyses were repeated, ascribing thimerosal exposure values of 100 μg for 1986 and of 0 μg for 1999. All of the results remained unchanged (data not shown).

Fourth, because some diagnostic misclassification could not be entirely ruled out and is more likely to occur with more atypical forms of PDD, such as PDDNOS or Asperger syndrome, we repeated the analyses on the subsample of 61 children with a diagnosis of autistic disorder. The results were similarly negative.

Autism and MMR

Vaccination uptake of MMR was high in Quebec, averaging 93.2% over the study years. Figure 1 illustrates the

lack of relationship between PDD rates in birth cohorts from 1987 to 1998 and MMR uptake estimates. There was a slight but significant trend toward a decrease in MMR uptake from 1988 to 1998 (χ^2 for trend = 80.7; $df = 1$; $P < .001$) with vaccine uptake dropping from ~96.1% in the older birth cohorts (1988–1989) to ~92.4% in younger birth cohorts (1996–1998). During the same period, a significant and linear increase in rates of PDD occurred (see above). Analyses were repeated on the subsample of 158 Quebec-born subjects who, considering the high MMR vaccine uptake in Quebec, were most likely to have been individually exposed to the MMR vaccination according to the official schedule of immunizations. As indicated above, prevalence rate of PDDs increased from 40.6 of 10 000 in 1987 to 102.5 of 10 000 in 1998, the linear increase being statistically significant (OR: 1.10; 95% CI: 1.05–1.16; $P < .0001$). Thus, PDD rates in Quebec-born children most certainly individually exposed to MMR vaccine increased at a time where MMR uptake decreased slightly, albeit significantly. As the schedule of MMR vaccination changed in 1996 with the addition of a second dose at 18 months of age, we performed 2 sets of analyses to assess whether PDD rates and MMR exposure were associated during the period of single MMR exposure only and to evaluate whether or not the introduction of a second MMR dose at 18 months of age from 1996 onward had any relationship with the trend in PDD prevalence. First, we examined the data after censoring the 1996–1998 birth cohorts to reassess the association within the context of a stable, single MMR dose exposure period. For the 1987–1995 birth cohorts, the increase in PDD rates still showed a statistically significant increase (OR: 1.15; 95% CI: 1.07–1.23; $P < .001$), whereas MMR vaccine uptake showed a small but significant downward trend during the corresponding interval (χ^2 for trend = 97.5; $df = 1$; $P < .001$) from ~96.1% in older birth cohorts (1988–1989) to 92.2% in younger birth cohorts (1994–1995). Thus, the data did not support any association between the single MMR dosing at 12 months of age and the PDD rate in these birth cohorts. Second, to test for a change in the rate of increase of PDD prevalence after the introduction of the 2-dose schedule in 1996, we performed 2 separate analyses. We modeled the prevalence data with multiple logistic regression using birth cohort (continuous), period (1987–1995 and 1996–1998), and the corresponding interaction term as predictors. In this model, the hypothesis of a change over time in the rate of increase of PDDs before and after 1996 is tested by evaluating the interaction term in the model. This interaction term was nonsignificant (Wald $\chi^2 = 3.14$; $df = 1$; $P > .05$), suggesting no difference in the upward trend before or after 1996. Then, we used the 1987–1995 prevalence rate series to predict what would be the prevalence estimates for the subsequent 3 years assuming that the linear increase in PDD rate observed from

1987 to 1995 remained constant. The predicted values and their associated 95% CIs for PDD rate were 108.1 of 10 000 (83.41–139.86 of 10 000), 123.8 of 10 000 (91.01–168.14 of 10 000), and 141.8 of 10 000 (99.10–202.4 of 10 000) for the years 1996, 1997, and 1998, respectively. Jackknife cross-validation showed very good robustness of the prediction model (data not shown). All of the actual observed prevalence estimates for these years fell below the predicted values, and in 2 instances (years 1996 and 1997), the observed prevalence estimates fell outside the predicted confidence limits. Thus, these combined results showed no indication that PDD prevalence in the 2-MMR dosing period had surpassed the values expected from the trend estimated from the single-MMR dosing period. Finally, we restricted our trend analysis to the 61 subjects with an autistic disorder diagnosis to evaluate the effects of potential diagnostic misclassification. In this subsample as well, a significant prevalence increase occurred from 1987 to 1998 (OR: 1.23; 95% CI: 1.13–1.34) at a time where the MMR uptake was decreasing significantly (see above). Thus, taken altogether, no association between MMR vaccinations (both 1 or 2 doses) and autism or PDD rates was suggested by these data.

DISCUSSION

Prevalence

The PDD prevalence estimate in this study was highly consistent with most recent surveys performed in several countries.^{6,7,10} This high figure was unexpected, because surveys that rely solely on administrative sources for case identification (eg, medical or educational records) usually yield lower prevalence estimates.⁷ Moreover, the rate in the 1998 birth cohort was >1% although the lower-bound limit of the CI was in the 0.6% to 0.7% range. Several factors could have influenced the prevalence in our study. First, diagnosis could not be directly confirmed, and it is therefore possible that PDD diagnoses were overused leading to diagnostic misclassification and overestimation of the prevalence. However, a large proportion of subjects included in this survey had been assessed and diagnosed in our pediatric hospital by different qualified professionals, limiting the extent of that possibility. In addition, the pattern of PDD diagnostic subtypes and gender correlates was fairly typical of other published samples. Second, special schools in Montreal that provide services to children with mental retardation, sometimes associated with PDD, were not included in the study, leading to a potential underestimation of the true population rate. However, because the school board has a policy of integration of children with even severe handicaps, especially at a young age, the magnitude of this downward bias likely remained small. Third, because the school board is known for its inclusive and supportive approach for children with

PDDs, it is possible that parents of children with PDDs may have migrated to the geographical catchment area of the school board to provide their children with better educational opportunities. Unfortunately, data about places of residence before registration to school were not available, precluding us from assessing whether selective migration into the local area by parents of children with PDDs might have occurred. The extent to which the previous possible biases cancel each other out cannot be gauged. Nevertheless, the estimate of 65 of 10 000 is highly consistent with other recent studies and shows that PDDs are relatively frequent disorders among children. Also, when PDDs were broken down by subtypes, a fairly typical pattern emerged with the prevalence of PDDNOS being 1.5 times higher than that for autistic disorder, and the prevalence of CDD being extremely low, consistent with available estimates.⁷ Our PDD rate cannot be directly compared with the only previous Canadian study,⁴⁴ because the 2 surveys differed in their case definition and methods of case ascertainment.

There was a statistically significant trend for increasing prevalence rates in younger birth cohorts (as indexed by grade attendance). On average, the prevalence rate increased by 10% annually over the 12 years of the study. This finding is consistent with trends in other studies that have repeatedly shown increasing prevalence rates in younger birth cohorts in the last 15 years.^{14,15} It cannot be concluded from this data whether a genuine increase in the incidence of the disorder in the population occurred during the study period, or increased ascertainment and broadened diagnostic criteria, or a combination of both factors applied. Nevertheless, 4 factors can be identified that may have given rise to this trend. First, new nosographies and diagnostic criteria were introduced in 1992 with *International Classification of Diseases, 10th Revision*,⁵⁸ and in 1994 with *DSM-IV*,¹ that broadened the category of PDD. The most obvious example is the introduction of the entirely new category of Asperger syndrome in both diagnostic schemes, a diagnosis that did not exist previously. The direct impact of using different diagnostic criteria on prevalence estimates has been well illustrated in a Finish study⁵⁹ where a twofold to threefold increase in prevalence resulted from applying old or new diagnostic criteria to the same survey data and subjects. Second, more expertise in diagnosing autism developed in the area with the establishment in recent years of a strong autism spectrum disorder clinical program at the Montreal Children's Hospital, the tertiary pediatric care institution that delivers services to Anglophone children. Third, a policy change at the MEQ level occurred in the summer of 2000 wherein the special education code 50 (PDD, as per DSM-IV) replaced the code 51 (autism, as per Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition) that had been in place for about a decade to identify PDD children with special needs and to pro-

vide additional funding for the schools.⁶⁰ This change made the new special education code pertaining to children with autism broader and applicable to a greater number of children, especially those diagnosed with either Asperger syndrome or PDDNOS who subsequently became eligible for extra support. Fourth, in 2000, because of initiatives related to autism already underway in the board, the LBPSB received the Center of Excellence for Autism recognition from the MEQ. This afforded the board the opportunity to further develop their expertise in diagnosis, treatment, and inclusion of students with PDDs, as well as required it to be a resource to the other Anglophone boards in the province. Combined altogether, these factors account most certainly for the upward trend in diagnoses in successive birth cohorts, although it is not possible to definitely rule out other explanations.⁷ It is of interest that similar factors (broadening of diagnostic criteria and changes in policy with the 1990 revision of the Individuals with Disabilities Educational Act) have been hypothesized by several authors to explain upward trends in rates of PDDs in recent US studies.^{13–15,61,62} With rates of 0.6% to 0.7%, PDDs are among the most prevalent conditions impairing young children's lives, translating to >50 000 Canadian children below age 20 years in need of services.

Thimerosal and Ethylmercury Exposure

During the 12 years encompassed by our study, thimerosal exposure before age 2 of each birth cohort changed several times and ranged from nil to a high value of 225 μg . This provided a unique opportunity to test the relationship of ethylmercury exposure with rates of PDDs, free of a known problem of vaccine safety studies when high rates of exposure in populations, and therefore low variability in exposure, constrain the data and limit the opportunity to detect effects.⁶³ No association between thimerosal levels treated either continuously or categorically with PDD rates could be found in our study. In fact, it was remarkable that the PDD rates were at their highest value in birth cohorts that were thimerosal free, providing a clear and convincing message on the lack of an association. The results were robust and held true when various analyses were conducted to evaluate the potential impact of misclassification on exposure and diagnosis. Within each period of medium, high, or nil exposure, the same trend toward a steady increase in PDD rate was observed, demonstrating total independence of the 2 variables. Our results are entirely consistent with cohort,^{30–33} case-control,⁶⁴ and other ecological studies performed in Denmark and Sweden.^{34,35} It is worth emphasizing 3 particular features of our results. First, because we were aware of limitations of ecological data, we performed complementary analyses on the subsample of Quebec-born subjects, a group with a very high probability of having been individually exposed to

the official vaccination schedule of their birth cohort. The results remained unchanged. Second, the PDD rate in our study was high and consistent with recent epidemiological estimates coming from the United States⁶⁵ and the United Kingdom.⁹ Thus, the convergence of our findings with those of the 2 ecological studies from Scandinavian countries^{34,35} suggests that the lack of association reported by these authors was not because of the lower prevalence of PDDs reported in their respective investigations. Third, exposure to ethylmercury in some birth cohorts of our study reached levels as high as those that were attained in the US immunization schedule in the 1990s and were higher than those ever reached in the United Kingdom and Scandinavian populations. Thus, the lack of association between PDD rate and high thimerosal exposure found in our study provides new evidence on the absence of an association between autism/PDD and high exposure levels to ethylmercury that is relevant to the North American public.

MMR and Autism

During the 11-year interval encompassed in our study, rates of PDD significantly increased, whereas MMR vaccine uptake showed a slight opposite trend. This finding is consistent with several other ecological studies that have tested an association between MMR vaccine uptake and rates of autism or PDD in the United Kingdom,^{21,23} in Japan,⁶⁶ in Sweden,⁶⁷ and in the United States.²² In this study, we were able to restrict the analysis to Quebec-born subjects who were most certainly individually exposed to MMR in light of the very high MMR uptake in Quebec throughout the period (93%). Thus, the usual limitations of ecological studies because of lack of information on individual exposure might not have applied to our study. It is also noteworthy that the MMR vaccine uptake actually declined in the study period, whereas the rates of PDD went up, both trends being significant. The opposite directions of both trends make it even less likely that a true association was not detected in our data. This, too, makes it less plausible that a positive association applying only to a small subset of PDD children would have gone unnoticed. Moreover, the change in the MMR schedule of immunization with the introduction of a second dose by the age of 18 months occurring in 1996 gave us opportunities to examine the effects of a 2-dose MMR schedule in infants. First, we established that the lack of association between MMR uptake and PPD rates applied to the period (1987–1995) where a single MMR dose was administered at 12 months of age. Thus, rates of PDD were rapidly increasing well before the introduction of the 2-dose schedule and, during that first phase, the increase of PDD rate bore no relationship with MMR vaccine uptake. Second, we tested whether the introduction of a second MMR dose after 1995 accelerated the increase in PDD rates in the following 3 years. No statistically significant differ-

ence could be found between the rate of increase in PDD prevalence between the 1-dosing and the 2-dosing periods. In fact, the end point prevalence estimate for 1998 was consistent with the value predicted on the basis of the 1987–1995 rate of increase. Therefore, 1 conclusion of this study is that 2-dosing schedule with MMR before age 2 is not associated with an increased risk of PDD.

Limitations

Several limitations of our study must be acknowledged. First, we relied on administrative codes for the diagnosis of PDDs, and children could not be individually assessed for diagnostic confirmation. Nevertheless, the majority of children attending this school board with a PDD diagnosis were diagnosed in the tertiary medical center where one of us (E.F.) leads a specialized assessment team, and, therefore, the diagnostic assessment of this sample should be viewed with confidence in many cases. Also, results remained unchanged when we restricted the analyses to subjects with a stricter diagnosis of autistic disorder, a subsample where diagnostic misclassification is unlikely to be occurring. Second, the study cannot control for whether or not the high number of children with PDDs identified in this survey reflects migrations into the schools from this particular school board that are known to have a proactive policy of integration and support of children with PDDs. If families of preschoolers were to change residence to access the schools within the LBPSB for their child's education, this might inflate the number of children with PDD in this school board. To test this hypothesis, data from other school boards should be obtained, and knowledge of the residence of the family at birth and before school entry could also help to address this issue. Unfortunately, this information was not available in the survey data that we could obtain. However, it is worth noting that if such migrations occurred, it might bias our prevalence estimates but would have no impact on the thimerosal and MMR analyses, because migration into the area must be independent of vaccination history. Third, data about regression in the course of the development of children with PDD were not available in this study, precluding us from assessing risk associations with immunizations specifically for this subgroup. Nevertheless, the claim that only this PDD subtype would be sensitive to thimerosal exposure cannot be supported, because a significant increase of PDDs continued in Montreal after total discontinuation of thimerosal, providing strong evidence that thimerosal does not increase the risk of PDD and, indeed, of any PDD variant. If thimerosal exposure was associated with an increase in the risk of the regressive subtype of autism (thought to apply to ~20% of PDD cases^{24,68}), then, at the very least, a slowing down in the upward trend in PDD rates should have been observed after 1996 when thimerosal was entirely removed from vaccine preparations. This was

not observed, and the upward trend continued in a linear fashion. Rates of PDDs were, in fact, higher in the thimerosal-free birth cohorts than in any preceding period where exposure to thimerosal was at either medium or high levels. With respect to MMR, the claim of a putative "autistic enterocolitis" regressive phenotype has already failed to be supported in other studies,^{24,69} and epidemiological studies have shown that the regressive phenotype of autism has not increased over time.^{24,69,70} Given this, our findings of a regular increase in PDD and autistic disorder prevalence while MMR vaccine uptake was decreasing during the study period are not consistent with any increase in the risk of PDD, regressive or not, that could be attributed to MMR.

Implications

There are several important implications of this study. First, our study adds additional evidence deriving from a large, population-based survey that PDDs are one of the most common developmental disorders in young children. With a prevalence of 0.6% to 0.7%, the service implications are straightforward. Second, as in other recent studies, factors such as broadening of diagnostic criteria, improved awareness about the disorder, changes in official social and educational policies, and improved access to services are certainly the primary driving force underlying the increasing prevalence figures.⁷ Yet, the possibility that a real change in the incidence could have occurred as well cannot be definitely ruled out from existing data. Third, our findings clearly failed to detect any relationship between thimerosal exposure and rates of PDDs. These findings concur with those from other similar ecological investigations^{34,35} and of more controlled epidemiological studies.^{25,38} Previous negative studies, especially those conducted in European countries, have sometimes been criticized on the account that either the rates of PDDs were not as high as those in North America, that the cumulative exposure to thimerosal was much lower than that attained in the United States in the 1990s, or both. This study avoids both pitfalls and is, therefore, very informative for the North American public. In addition, the rate of exposure varied from nil to very high levels of vaccine-derived ethylmercury, allowing us to test for effects along the full range of exposure and to detect possible threshold effects as well. All of the results were negative. Fourth, as in previous studies,²⁵ no effect of MMR vaccine could be detected on the risk of PDD. The trends went in opposite directions, making it unlikely that even small effects applying to a small subset of children would exist. Furthermore, this study added new evidence suggesting that the 2-MMR dose schedule before age 2 years also had no impact on rates of PDD. Fifth, parents of children with PDD and the general public should be made aware of the consistency of negative studies on the 2 hypotheses linking risk of autism and immunizations. Children

with autism and their younger unaffected siblings should be vaccinated. Unvaccinated children are at much higher risk of contracting measles and suffering from its sometimes severe or lethal complications.⁷¹ There is no evidence for an epidemiological association between ethylmercury and autism and no scientific basis for using chelation therapies, which can be dangerous. Decreasing MMR uptake in the British isles has led to more frequent measles outbreaks of greater magnitude²⁷ and to children's deaths.⁷² Findings of negative studies are, indeed, more difficult to convey, but, here, the evidence lies in the striking convergence of studies accumulated by different groups, with different designs and in different places.

ACKNOWLEDGMENTS

Dr Fombonne's salary support is partially funded through the Canada Research Chair Canadian Institutes for Health Research (to Dr Fombonne and McGill University).

We are indebted to Dr Monique Landry from the Direction Générale de la Santé Publique of Montreal, Ministère de la Santé et des Services Sociaux, for her assistance in obtaining precise data on the immunization schedules in Quebec and to Nicole Boulianne de la Direction de Santé Publique de la Capitale Nationale for providing data on MMR uptake surveys.

REFERENCES

- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4th ed. Washington, DC: American Psychiatric Association; 1994
- Muhle R, Trentacoste SV, Rapin I. The genetics of autism. *Pediatrics*. 2004;(113). Available at: www.pediatrics.org/cgi/content/full/113/5/e472
- National Research Council. *Educating Children With Autism*. Washington, DC: National Academy Press; 2001
- Smith T, Groen AD, Wynn JW. Randomized trial of intensive early intervention for children with pervasive developmental disorder. *Am J Ment Retard*. 2000;105:269–285
- Howlin P, Goode S, Hutton J, Rutter M. Adult outcome for children with autism. *J Child Psychol Psychiatry*. 2004;45:212–229
- Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. *J Autism Dev Disorder*. 2003a;33:365–382
- Fombonne E. Epidemiological studies of autism and pervasive developmental disorders. In: Volkmar F, ed. *Handbook of Autism and Pervasive Developmental Disorders*. 3rd ed. New York, NY: Wiley & Sons; 2005:42–69
- Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. *JAMA*. 2001;285:3093–3099
- Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. *Am J Psychiatry*. 2005;162:1133–1141
- Fombonne E. The prevalence of autism. *JAMA*. 2003;289:1–3
- Fombonne E. Is there an epidemic of autism? *Pediatrics*. 2001;107:411–413
- Gernsbacher MA, Dawson M, Goldsmith HH. Three reasons not to believe in an autism epidemic. *Curr Dir Psychol Sci*. 2005;14:55–58
- Barbarese WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. The incidence of autism in Olmsted County, Minnesota, 1976–1997: results from a population-based study. *Arch Pediatr Adolesc Med*. 2005;159:37–44
- Gurney JG, Fritz MS, Ness KK, Sievers P, Newschaffer CJ, Shapiro EG. Analysis of prevalence trends of autism spectrum disorder in Minnesota. *Arch Pediatr Adolesc Med*. 2003;157:622–627
- Newschaffer CJ, Falb MD, Gurney JG. National autism prevalence trends from United States special education data. *Pediatrics*. 2005;115(3). Available at: www.pediatrics.org/cgi/content/full/115/3/e277
- Arndt TL, Stodgell CJ, Rodier PM. The teratology of autism. *Int J Dev Neurosci*. 2005;23:189–199
- Wakefield A, Murch S, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. *Lancet*. 1998;351:637–641
- Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. *N Engl J Med*. 2002;347:1477–1482
- Smeeth L, Cook C, Fombonne E, et al. MMR vaccination and pervasive developmental disorders: a case-control study. *Lancet*. 2004;364:963–969
- DeStefano F, Bhasin TK, Thompson WW, Yeargin-Allsopp M, Boyle C. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. *Pediatrics*. 2004;113:259–266
- Chen W, Landau S, Sham P, Fombonne E. No evidence for links between autism, MMR and measles virus. *Psychol Med*. 2004;34:543–553
- Dales L, Hammer S, Smith N. Time trends in autism and MMR immunization coverage in California. *JAMA*. 2001;285:1183–1185
- Taylor B, Miller E, Farrington C, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. *Lancet*. 1999;353:2026–2029
- Fombonne E, Chakrabarti S. No evidence for a new variant of measles-mumps-rubella-induced autism. *Pediatrics*. 2001;108(4). Available at: www.pediatrics.org/cgi/content/full/108/4/e58
- Institute of Medicine. *Immunization Safety Review: Vaccines and Autism*. Washington, DC: National Academies Press; 2004
- Demicheli V, Jefferson T, Rivetti A, Price D. Vaccines for measles, mumps and rubella in children. *Cochrane Database Syst Rev*. 2005;(4):CD004407
- Jansen VA, Stollenwerk N, Jensen HJ, Ramsay ME, Edmunds WJ, Rhodes CJ. Measles outbreaks in a population with declining vaccine uptake. *Science*. 2003;301:804
- Ball L, Ball R, Pratt D. An assessment of thimerosal use in childhood vaccines. *Pediatrics*. 2001;107:1147–1154
- Halsey NA, Hyman SL, Conference Writing P. Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12–13, 2000. *Pediatrics*. 2001;107(5). Available at: www.pediatrics.org/cgi/content/full/107/5/e84
- Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association. *Pediatrics*. 2004;114:584–591
- Heron J, Golding J. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a causal association. *Pediatrics*. 2004;114:577–583
- Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association be-

- tween thimerosal-containing vaccine and autism. *JAMA*. 2003; 290:1763–1766
33. Verstraeten T, Davis RL, DeStefano F, et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. *Pediatrics*. 2003; 112:1039–1048
 34. Madsen KM, Lauritsen MB, Pedersen CB, et al. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. *Pediatrics*. 2003;112:604–606
 35. Stehr-Green P, Tull P, Stellfeld M, Mortenson PB, Simpson D. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. *Am J Prev Med*. 2003;25:101–106
 36. Geier DA, Geier MR. Thimerosal in childhood vaccines, neurodevelopmental disorders, and heart disease in the United States. *J Am Phys Surg*. 2003;8:6–11
 37. Geier DA, Geier MR. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. *Pediatr Rehabil*. 2003;6:97–102
 38. Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. *Pediatrics*. 2004;114:793–804
 39. Ip P, Wong V, Ho M, Lee J, Wong W. Mercury exposure in children with autistic spectrum disorder: case-control study. *J Child Neurol*. 2004;19:431–434
 40. Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. *Lancet*. 2002;360: 1737–1741
 41. Kennedy RF Jr. Deadly immunity. Available at: www.rollingstone.com/politics/story. Accessed June 20, 2005
 42. Kirby D. *Evidence of Harm: Mercury in Vaccines and the Autism Epidemic—A Medical Controversy*. New York, NY: St. Martin's Press; 2005
 43. Associated Press. Boy with autism dies after chelation therapy. Available at: www.msnbc.msn.com/id/9074208. Accessed May 12, 2006
 44. Bryson SE, Clark BS, Smith IM. First report of a Canadian epidemiological study of autistic syndromes. *J Child Psychol Psychiatry*. 1998;4:433–445
 45. Ministère de la Santé et des Services Sociaux du Québec. *Protocole d'immunisation du Québec*. 1st ed. 2nd revision. Ministère de la Santé et des Services Sociaux du Québec; 1992
 46. Ministère de la Santé et des Services Sociaux du Québec. *Protocole d'immunisation du Québec*. Québec, Canada: Ministère de la Santé et des Services Sociaux du Québec; 1995
 47. Ministère de la Santé et des Services Sociaux du Québec. *Protocole d'immunisation du Québec*. 2nd ed, avril 1995, ainsi que ses mises à jour décembre 1995 et octobre. Québec, Canada: Ministère de la Santé et des Services Sociaux du Québec; 1997
 48. Ministère de la Santé et des Services Sociaux du Québec. *Protocole d'immunisation du Québec*. 4th ed, avril 1999, ainsi que ses mises à jour avril; Québec, Canada: Ministère de la Santé et des Services Sociaux du Québec; 2002
 49. Ministère de la Santé et des Services Sociaux du Québec. *Protocole d'immunisation du Québec*. 5th ed, avril 2004, ainsi que ses mises à jour septembre et novembre 2004. Available at: www.msss.gouv.qc.ca/sujets/santepub/preventioncontrole/immunisation/fs.immunisation.html. Accessed January 30, 2006
 50. Hudson P, Allard R, Joseph L, Valiquette L. Vaccine coverage of 2-year-old children in Montreal, 2003. Communication at the 6th Canadian Immunization Conference; December 5–8, 2004; Montreal, Quebec, Canada
 51. Charbonneau S, Riou D, Grignon R. Enquête vaccinale auprès des enfants de 2–2½ ans du territoire du DSC Cité de la Santé de Laval. Laval, Québec, Canada: Département de Santé Communautaire; 1987:51
 52. Landry M, Valiquette L, Allard R, Cionti M, Chrétien S. Enquête sur la couverture vaccinale des enfants de 24–30 mois. DSC Cité de la Santé de Laval et DSC Maisonneuve-Rosemont; Presented at: the 3rd Quebec Colloquium of Infectious Disease; Quebec, Canada; November 1992
 53. Lafontaine G, Sauvageau Y. Couverture vaccinale des enfants âgés de 2 ans du territoire du DSC de l'Hôpital Charles Lemoyne. Québec, Canada: Département de Santé Communautaire de l'Hôpital Charles Lemoyne; 1990:36
 54. Marin-Lira A, Soto JC. Un regard aux études sur la couverture vaccinale au Québec. Document de travail. Québec, Canada: Direction de la Santé Publique de Laval; 1996:24
 55. De Wals P, De Serres G et Niyonsenga T. Effectiveness of a Mass immunization campaign against serogroup C meningococcal disease in Quebec. *JAMA*. 2001;285:177–181
 56. SAS Institute. *SAS/STST User's Guide, Version 6*. 4th ed. Vol 2. Cary, NC: SAS Institute; 1990
 57. Allison P. Logistic regression using the SAS system: theory and application. Cary, NC: SAS Institute Inc and John Wiley; 2001
 58. World Health Organization. *The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines*. Geneva, Switzerland: World Health Organization; 1992
 59. Kielinen M, Linna S-L, Moilanen I. Autism in Northern Finland. *Eur Child Adolesc Psychiatr*. 2000;9:162–167
 60. Direction de l'adaptation scolaire et des services complémentaires. *Students With Handicaps, Social Maladjustments, or Learning Difficulties: Definitions*. Gouvernement du Québec. Ministère de l'Éducation, 2000-00-0078. Québec, Canada: Bibliothèque Nationale du Québec; 2000
 61. Croen LA, Grether JK, Hoogstrate J, Selvin S. The changing prevalence of autism in California. *J Autism Dev Disord*. 2002; 32:207–215
 62. Laidler JR. US Department of Education data on "autism" are not reliable for tracking autism prevalence. *Pediatrics*. 2005; 116:120–124
 63. Smeeth L, Rodrigues LC, Hall AJ, Fombonne E, Smith PG. Evaluation of adverse effects of vaccines: the case-control approach. *Vaccine*. 2002;20:2611–2617
 64. Jick H, Kaye JA. Autism and DPT vaccination in the United Kingdom. *N Engl J Med*. 2004;350:2722–2723
 65. Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, Decoufle P. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. *Pediatrics*. 2001; 108:1155–1161
 66. Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. *J Child Psychol Psychiatry*. 2005;46:572–579
 67. Gillberg C, Heijbel H. MMR and autism. *Autism*. 1998;2: 423–424
 68. Lord C, Shulman C, DiLavore P. Regression and word loss in autistic spectrum disorders. *J Child Psychol Psychiatry*. 2004;45: 936–955
 69. Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. *BMJ*. 2002;324:393–396
 70. Fombonne E, Heavey L, Smeeth L, et al. Validation of the diagnosis of autism in general practitioner records. *BMC Public Health*. 2004;4:5
 71. Salmon DA, Haber M, Gangarosa EJ, Phillips L, Smith NJ, Chen RT. Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. *JAMA*. 1999;282:47–53
 72. McBrien J, Murphy J, Gill D, Cronin M, O'Donovan C, Cafferkey MT. Measles outbreak in Dublin, 2000. *Pediatr Infect Dis J*. 2003;22:580–584

Pervasive Developmental Disorders in Montreal, Quebec, Canada: Prevalence and Links With Immunizations

Eric Fombonne, Rita Zakarian, Andrew Bennett, Linyan Meng and Diane McLean-Heywood

Pediatrics 2006;118:139-150

DOI: 10.1542/peds.2005-2993

This information is current as of August 1, 2006

Updated Information & Services

including high-resolution figures, can be found at:
<http://www.pediatrics.org/cgi/content/full/118/1/e139>

References

This article cites 46 articles, 21 of which you can access for free at:
<http://www.pediatrics.org/cgi/content/full/118/1/e139#BIBL>

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):
Infectious Disease & Immunity
http://www.pediatrics.org/cgi/collection/infectious_disease

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
<http://www.pediatrics.org/misc/Permissions.shtml>

Reprints

Information about ordering reprints can be found online:
<http://www.pediatrics.org/misc/reprints.shtml>

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

